circulatory support News
-
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting
CorWave, a French medical device company committed to the fight against heart failure, announced that it has successfully completed the first 90-day preclinical study to evaluate its left ventricular assist device (LVAD) operating synchronously with the native heart without the use of sensors. The results were presented at the American Society for Artificial Internal Organs (ASAIO) Annual Meeting ...
By CorWave
-
CARMAT announces the first implant of its Aeson total artificial heart in The Netherlands
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the first implant of theAeson artificial heart in The Netherlands. The implant procedure was performed by theHeart Team led ...
By Carmat
-
Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention ...
-
Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function ...
-
Berlin Heart Received CE Mark and Announces First Implantation of the Latest Cannula Generation to Treat Heart Patients Waiting for a Donor Heart
Berlin, September 2021: Berlin Heart today announces the CE mark and first implantation of an innovative outflow cannula for mechanical circulatory support with the paracorporeal pulsatile EXCOR® ventricular assist device. The EXCOR® Graft Cannula* connects the outflow side of the blood pump to the ascending aorta for left ventricular support or to the pulmonary artery for right ...
-
Procyrion Receives FDA Breakthrough Device Designation for Aortix™ System
Procyrion, Inc., a medical device company developing percutaneous circulatory support devices for the treatment of heart failure, announced today that it has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Aortix™ System. Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized ...
-
Procyrion Named Most Innovative Heart Pump Technology In 2018 Global Healthcare and Pharmaceutical Awards
Houston medical device developer Procyrion Inc. today announced they have won the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients. The award celebrates the contributions made by ...
-
CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor
CorWave raises 35 million euros to fund the next stages of its development, with the ambition to become a world-class medtech company serving heart failure patients. The capital increase is subscribed by returning investors joined by the EIC Fund, the European Commission's venture capital mega-fund, which makes its first investment. CorWave, located in Clichy, Île-de-France, is developing ...
By CorWave
-
4Q 2021 Stakeholder Update
Progress Update December 27th, 2021 Year End Summary 2021 was a great year of progress for Second Heart Assist, Inc. We completed a large series of large animals with long duration use at Texas Heart Institute with great success. We believe we are set now to begin a cardio-renal syndrome clinical study with 24 hours circulatory assist support time in 1Q 2022. Our team believes we are in the ...
-
CARMAT announces a new commercial implant of its Aeson artificial heart at University Medical Center Schleswig-Holstein in Kiel, Germany
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new commercial implant of the Aeson® device was ...
By Carmat
-
Berlin Heart triples staff member donations and secures `Films for life` project financing
For many Berlin Heart staff members, providing ventricular assist devices for people who are waiting for a donor heart is more than just a job. Extending the lives of patients and giving them quality of life despite all circumstances is the motivation that drives many Berlin Heart staff members on a daily basis. Raising awareness for the issue of organ donation is therefore close to their hearts, ...
-
Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart
Montreal-based Puzzle Medical Devices Inc., announced today the successful completion of the company’s ?rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). Four patients had ModulHeart deployed to provide circulatory support while undergoing ...
-
Procyrion’S Aortix Percutaneous Mechanical Circulatory Support Device to be Showcased at Tct 2021 Annual Meeting
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the schedule of presentations to be featured at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Orlando, Florida from November 4th to November 6th. The presentations include a spotlight on the company’s first US case treating a ...
-
CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting
CorWave announced today that the latest results of its preclinical Left Ventricular Assist Device (LVAD) development program are presented at the 2020 Virtual OnDemand Conference of the American Society for Artificial Organs (ASAIO), in the Top Abstracts session, available on the ASAIO website1. The presentation, entitled “In Silico, In Vitro and In Vivo Evaluation of the CorWave Membrane ...
By CorWave
-
Saranas Recognized as One of Houston’s Most Innovative Companies
Saranas Inc., a medical device company pioneering technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been named one of Houston’s most innovative companies. Saranas is the only medical device company to be honored at the inaugural Innovation Awards presentation sponsored by the Houston Business Journal on ...
-
Endotronix Hires Industry Veteran Jim Yearick as Senior Vice President of Sales and Marketing
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that industry veteran Jim Yearick has joined the executive leadership team as Senior Vice President of Sales and Marketing. Mr. Yearick will oversee Endotronix’s worldwide sales and marketing efforts for the Cordella™ Heart Failure System (Cordella ...
-
Berlin Heart Enrolls First Patients in Clinical Study to Investigate Innovative Mobilization Option for Children Waiting for a Heart Transplantation
Berlin Heart is pleased to announce that the first patients are enrolled in the "E-MOTION" study: “The use of the EXCOR® Active driving unit for MObilizaTION of pediatric patients with Ventricular Assist Device support”. This observational, international, multi-center study investigates the improved mobility, patient outcome and the impact of the mobile driving concept ...
-
CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up
CorWave, a French medtech developing a next-generation heart pump, is recruiting top talent from throughout the world to strengthen its team. Two seasoned industry experts are joining the company: Paul Cornelison (USA) as Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs, and Michael Webb (Australia) as Vice President, Manufacturing. Paul Cornelison and Michael Webb have ...
By CorWave
-
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation
CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). The company presented the first ever study demonstrating sensorless synchronization of a pericardial pump with the native heart for ...
By CorWave
-
First human implant of the Aeson artificial heart in Germany
The implant was performed at Hannover Medical School. Paris, July 26, 2021 – 6:00 pm CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic artificial ...
By Carmat
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you